SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on June 30, 2023 and is headquartered in Dallas, TX.

Solidion Technology Inc

Solidion Technology is trending due to news of its advanced UPS battery system tailored for AI data centers, sparking significant community interest. Traders are drawn to the stock's low float and potential for a short squeeze, drawing comparisons to other high-momentum stocks in the battery and energy sectors like $ELBM and $GWH. Community members are actively discussing its potential impact on the AI data center market.

Electra Battery Materials Corp. engages in the refining, acquisition, and exploration of resource properties. Its project portfolio includes Iron Creek and Battery Materials Park. The company was founded on July 13, 2011 and is headquartered Toronto, Canada.

Electra Battery Materials Corp

Electra Battery Materials is trending as community members discuss its potential for a short squeeze and compare it to other stocks in the same sector like $STI and $GWH. Bullish sentiment is fueled by news of secured financing and government backing for its cobalt refinery project. Traders are actively watching price levels and potential breakouts, with some anticipating a multi-day run.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast ($MVST) is trending as the community discusses its potential for significant growth, highlighting its small float, low short interest, and progress in EU revenues. Some believe the stock is undervalued compared to competitors like $QS and are anticipating a substantial move towards higher valuations, possibly reaching three-digit figures long term. Bullish sentiment is fueled by positive technical indicators and upcoming Q3 earnings, with some eyeing a potential short squeeze.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as trade tensions with China escalate, spotlighting the importance of domestic antimony supply for national security and defense. Community members are discussing potential government investments and contracts, alongside the company's expansion plans. With China cutting off antimony exports, UAMY, a key U.S. producer, is gaining attention, fueling speculation of significant growth.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as shares trade higher following the announcement of a partnership with Tsecond to deliver AI-enabled edge infrastructure. The community is buzzing with excitement, anticipating a potential short squeeze and further upside, with some eyeing double-digit prices soon. Discussions also include the company's strong backlog and cash position, fueling speculation about upcoming government contracts.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending amid community excitement and speculation about its potential within the AI and data center power infrastructure, with some linking it to Nvidia. Bullish investors are pointing to increasing volume, potential breakout, and long-term growth prospects, while others discuss potential pullbacks and upcoming earnings.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies behind the OG meme coin, emphasizing its resilience amid market volatility. Discussions highlight the strength of the community, with many expressing bullish sentiment and encouraging others to embrace the 'rage' and 'send it' to new heights. The return of rage comics and memetic energy are central to the current conversation.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is gaining traction, with community members actively discussing its potential and strong mindshare, while also commenting on the recent market volatility. Some are highlighting its resilience, the strength of its community, and comparing it to other meme coins on the Solana blockchain. The project's website is being shared as a resource for those looking to learn more.

American Resources Corp. engages in the extraction, processing, transportation, and distribution of metallurgical coal to the steel industry. It focuses on the operation of coal mining complexes located primarily within Pike, Knott, and Letcher Counties, Kentucky, and Wyoming County, West Virginia. The company was founded in 2006 and in headquartered in Fishers, IN.

American Resources Corporation - Ordinary Shares - Class A

American Resources Corporation (AREC) is trending as investors discuss its potential in the rare earth element sector following a recent private placement to fund its initiatives; the community is focused on its potential to break through the $5 mark and its ReElement subsidiary's upcoming IPO, with some highlighting potential short squeeze opportunities and the broader context of domestic rare earth production amid geopolitical tensions.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms ($BITF) is trending as investors discuss its potential in the AI/HPC infrastructure space, particularly following a price target increase from Northland. Community members are actively debating its valuation relative to peers like $IREN and the impact of potential AI contracts. Bullish sentiment is fueled by the company's 1.3 GW project pipeline and growing interest in AI-related stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent...

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit US equity futures are slightly higher , hovering near all time highs as traders bet that data on Friday will bolster the case for interest rate...

Precigen, Inc. (PGEN) said on Friday that the US Food and Drug Administration (FDA) has approved its immunotherapy Papzimeos for the treatment of adults with recurrent respiratory papillomatosis (RRP).Recurrent respiratory papillomatosis (RRP) is a rare condition where benign, wart-like tumors, called papillomas, grow in the respiratory tract, most commonly the larynx or the voice box. The disease can lead to severe voice disturbance, a compromised airway, and recurrent post-obstructive pneumonias. According to Precigen, there are about 27,000 adult RRP patients in the U.S.Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with RRP, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/precigen-announces-full-fda-approval-of-papzimeos-zopapogene-imadenovec-drba-the-first-and-only-approved-therapy-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-302530957.html">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PGEN">Precigen</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. Shares of the company traded 50% higher in the pre-market session at the time of writing.“With the landmark FDA approval of Papzimeos and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," said CEO Helen Sabzevari. Management of RRP, the company said, previously primarily consisted of repeated surgeries that did not address its root cause.The FDA approval was supported by data from an open-label, single-arm study in adult patients with RRP in which 51% of study patients required no surgeries in the 12 months after treatment with Papzimeos. Further, the therapy was well-tolerated in the trial with no serious treatment-related adverse events.Precigen noted that no confirmatory clinical trial is required for the therapy, which is delivered via four subcutaneous injections over a 12-week interval. The company added that it will begin promoting Pazimeos immediately.H.C. Wainwright subsequently raised its price target on Precigen to $8.50 from $6 while keeping a 'Buy' rating on the shares. The firm expects the drug to generate sales of $1.1 billion in 2033 from $138 million in 2026.PGEN stock is up by 65% this year and by about 73% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-climbs-premarket-even-after-warren-buffett-s-berkshire-trims-stake/chsPjsBRdf9">Apple Stock Climbs Premarket Even After Warren Buffett’s Berkshire Trims Stake</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why

The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. 

Equity

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 FDA Grants...

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at...

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 9, 2025 GERMANTOWN...

Small-cap, clinical-stage biopharma Precigen, Inc. ($PGEN) rallied on Monday following a regulatory update. The stock ended the session 28.47% higher at $0.9331 on more than six times the average volume.Germantown, Maryland-based Precigen announced the completion of the rolling submission for a biologic license application (BLA) for PRGN-2012, a gene therapy being investigated as a treatment option for adult patients with recurrent respiratory papillomatosis (RRP).RRP is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx, and it is caused by the human papillomavirus (HPV) 6 or HPV 11. It can prove fatal.&nbsp;Precigen said the BLA is now in the initial 60-day review period and the FDA will decide whether to accept the application for further review and set the Prescription Drug User Fee Act (PDUFA) date by this period.The company also noted that the application included a request for priority review, which, if granted, will reduce the review period from 10 months to six months.PRGN-2012 acts by eliciting immune responses directed against cells infected with HPV 6 or HPV 11. The company noted that there is no cure for the condition currently and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease.&nbsp;The regulatory application is supported by pivotal Phase 1/2 study results, which showed more than 50% of patients achieved complete response and more than 85% had a decrease in surgical interventions the year after the treatment.&nbsp;Helen Sabzevari, President and CEO of Precigen, "We look forward to working closely with the FDA on next steps now that we have completed the BLA submission and we are excited by the potential to bring PRGN-2012 to RRP patients as quickly as possible."'The executive also said, with the recent $79 million private placement of convertible preferred stock, the company has extended its cash runway into 2026, well beyond the potential commercial launch in the second half of 2025.<figure class="image"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/pgen_sentiment_0fbe6731dd.png" alt="pgen-sentiment.png" width="637" height="135"><figcaption>PGEN sentiment and message volume December 31, 2024, as of 3:36 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward Precigen flipped from ‘extremely bearish’ a day ago to ‘extremely bullish’ (96/100), the highest in a year. Message volume also spurted from ‘normal’ to ‘extremely high.’In a message posted on the PGEN stream on Stocktwits, a user said they looked ahead to a good 2025 for the company.&nbsp;<stembedurl>https://stocktwits.com/ASTAD13/message/598217372</stembedurl>If the company manages to get a priority voucher, it can resell it for $100 million, another noted.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/598207700</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/analyst-picks-pegasystems-stock-among-top-10-tech-winners-of-2025/cJO1z97Rkm">Analyst Picks Pegasystems Stock Among Predicted Top 10 Tech Winners Of 2025: Retail Shares The Optimism</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally

Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis Precigen Completes Submission of...

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$3.19
Prev Close	$3.12
Open	$3.25
Dividend Yield	0.00%
50-Day Moving Average	$3.38
Beta	1.94
Avg. Volume	6.65M
PE Ratio	-7.28

52-Week High	$5.23
52-Week Low	$0.6513
Market Capitalization	$929.68M
EPS (Annual)	-$0.4715
Price to Book	-25.27
Revenue Per Employee	$27,447.55
Enterprise Value/EBITDA	N/A

PGEN
Precigen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PGEN News

PGENPrecigen Inc